*New additions in COPD Management* *2. Ensifentrine is a novel inhaled dual inhibitor of Phosphodiesterase 3 and phophodiesterase 4.* It has anti-inflammatory and bronchodilator properties. It is only available in nebulizer form. Ensifentrine improves lung functions and dyspnea but it has inconsistent effects of quality of life. *#medlung Talks 🫁*